JP2008508353A5 - - Google Patents

Download PDF

Info

Publication number
JP2008508353A5
JP2008508353A5 JP2007524768A JP2007524768A JP2008508353A5 JP 2008508353 A5 JP2008508353 A5 JP 2008508353A5 JP 2007524768 A JP2007524768 A JP 2007524768A JP 2007524768 A JP2007524768 A JP 2007524768A JP 2008508353 A5 JP2008508353 A5 JP 2008508353A5
Authority
JP
Japan
Prior art keywords
benzo
dihydro
phenyl
tetrahydro
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007524768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508353A (ja
Filing date
Publication date
Priority claimed from SE0401971A external-priority patent/SE0401971D0/xx
Application filed filed Critical
Publication of JP2008508353A publication Critical patent/JP2008508353A/ja
Publication of JP2008508353A5 publication Critical patent/JP2008508353A5/ja
Abandoned legal-status Critical Current

Links

JP2007524768A 2004-08-02 2005-07-27 ヒスタミンh3受容体リガンドとしてのピペリジン誘導体 Abandoned JP2008508353A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0401971A SE0401971D0 (sv) 2004-08-02 2004-08-02 Piperidne derivatives
PCT/SE2005/001189 WO2006014136A1 (en) 2004-08-02 2005-07-27 Piperidine derivatives as histamine h3 receptor ligands

Publications (2)

Publication Number Publication Date
JP2008508353A JP2008508353A (ja) 2008-03-21
JP2008508353A5 true JP2008508353A5 (enExample) 2009-03-12

Family

ID=32906883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007524768A Abandoned JP2008508353A (ja) 2004-08-02 2005-07-27 ヒスタミンh3受容体リガンドとしてのピペリジン誘導体

Country Status (14)

Country Link
US (1) US20080064706A1 (enExample)
EP (1) EP1781613A1 (enExample)
JP (1) JP2008508353A (enExample)
KR (1) KR20070043998A (enExample)
CN (1) CN1993325A (enExample)
AU (1) AU2005267932A1 (enExample)
BR (1) BRPI0514035A (enExample)
CA (1) CA2576112A1 (enExample)
IL (1) IL180548A0 (enExample)
MX (1) MX2007001226A (enExample)
RU (1) RU2007105970A (enExample)
SE (1) SE0401971D0 (enExample)
WO (1) WO2006014136A1 (enExample)
ZA (1) ZA200700683B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026844A1 (en) 2003-04-03 2005-02-03 Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
WO2005089380A2 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
CA2596393C (en) 2004-12-30 2014-09-23 Janssen Pharmaceutica N.V. 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase for the treatment of anxiety, pain and other conditions
AU2006275568A1 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
CN101784529A (zh) * 2007-06-22 2010-07-21 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的脲和氨基甲酸酯衍生物
CA2705502C (en) 2007-11-13 2016-01-26 Taisho Pharmaceutical Co., Ltd. Phenylpyrazole derivatives
US8598356B2 (en) 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
TW201039822A (en) 2009-02-06 2010-11-16 Taisho Pharmaceutical Co Ltd Dihydroquinolinone derivatives
JP5778168B2 (ja) 2009-12-04 2015-09-16 スノビオン プハルマセウトイカルス インコーポレイテッド 多環式化合物及びその使用方法
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2012113103A1 (en) * 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
TW201321353A (zh) 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
AU2012349290B2 (en) 2011-12-08 2017-03-23 Taisho Pharmaceutical Co., Ltd. Phenylpyrrole derivative
WO2013100054A1 (ja) 2011-12-27 2013-07-04 大正製薬株式会社 フェニルトリアゾール誘導体
US9034874B2 (en) * 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
TWI690512B (zh) * 2014-03-07 2020-04-11 瑞士商赫爾辛保健股份有限公司 對位取代的不對稱脲及其醫療用途
JP6616786B2 (ja) 2014-05-19 2019-12-04 メリアル インコーポレイテッド 駆虫性化合物
US10752587B2 (en) 2015-12-01 2020-08-25 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use
KR102640774B1 (ko) 2016-03-22 2024-02-26 헬신 헬쓰케어 에스.에이. 벤젠술포닐-비대칭 우레아 및 그의 의학적 용도
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
CN116283877A (zh) 2016-07-29 2023-06-23 赛诺维信制药公司 化合物、组合物及其用途
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
AR110770A1 (es) 2017-01-23 2019-05-02 Cadent Therapeutics Inc Moduladores del canal de potasio
JP7146782B2 (ja) 2017-02-16 2022-10-04 サノビオン ファーマシューティカルズ インク 統合失調症を処置する方法
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. ISOCHROMANE COMPOUNDS AND THEIR USES
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
PE20201448A1 (es) 2018-04-18 2020-12-10 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
KR20210080446A (ko) 2018-10-22 2021-06-30 카덴트 테라퓨틱스, 인크. 칼륨 채널 조절제의 결정 형태
CN111349609A (zh) * 2018-12-21 2020-06-30 泰州医药城国科化物生物医药科技有限公司 一种无标记组胺受体h3的细胞筛选模型
EP3938045A1 (en) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
US20220305006A1 (en) * 2019-05-13 2022-09-29 The Regents Of The University Of California Compositions and methods for the treatment of neurological diseases and disorders
ES2819309B2 (es) * 2019-10-14 2021-11-17 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas
IL297248A (en) 2020-04-14 2022-12-01 Sunovion Pharmaceuticals Inc (s)-(5,4-dihydro-7h-thiano[3,2-c]pyran-7-yl)-n-methylmethanamine for the treatment of neurological and psychiatric disorders
CN113549006B (zh) * 2020-04-26 2023-07-21 江苏恩华药业股份有限公司 一种酰胺衍生物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343307A1 (en) * 1988-05-26 1989-11-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. 4-Piperidinealkanamine derivatives
DE19614204A1 (de) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1434765B1 (en) * 2001-09-14 2009-12-02 High Point Pharmaceuticals, LLC Substituted piperidines with selective binding to histamine h3-receptor
US6673829B2 (en) * 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US7064135B2 (en) * 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
AU2003274053A1 (en) * 2002-10-22 2004-05-13 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
JP4765627B2 (ja) * 2003-09-22 2011-09-07 Msd株式会社 新規ピペリジン誘導体

Similar Documents

Publication Publication Date Title
JP2008508353A5 (enExample)
CN100418951C (zh) 环胺衍生物及其作为药物的用途
JP4753403B2 (ja) インテグリンのそのレセプターへの結合を阻害する化合物
ES2291464T3 (es) Derivados de n-(arilsulfonil)beta-aminoacidos que comprenden un grupo aminoetilo sustituido, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
RU2007105970A (ru) Пиперидиновые производные в качестве лигандов гистаминового из рецептора
ES2240339T3 (es) Derivados de oxibenzamidas en calidad de inhibidores de factor xa.
KR100927563B1 (ko) 방향족 화합물
JP2008508352A5 (enExample)
JP2004520435A (ja) 新規非イミダゾール化合物
RU2003127723A (ru) Ацилированные 6, 7, 8, 9 - тетрагидо - 5h - бензоциклогептениламины и их применение в качестве фармацевтических препаратов
US20070225292A1 (en) Therapeutic Compounds: Pyridine as Scaffold
US20070249618A1 (en) Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression
SK16152002A3 (sk) Farmacueticky účinné piperidínové deriváty, najmä ako modulátory aktivity chemokínového receptora
KR20070091174A (ko) 유기 화합물
PT2207773E (pt) Composto heterocíclico e composição farmacêutica que contém o mencionado composto
JPWO2006057270A1 (ja) 含窒素3環化合物
JPWO2004101514A1 (ja) シアノフルオロピロリジン誘導体
CN100422151C (zh) 二芳基亚甲基哌啶衍生物、其制备及其用途
ES2286474T3 (es) Derivados de 4-(finilpiperazinilmetil) benzamida y su uso para el tratamiento de dolor o transtornos gastrointestinales.
KR20080013933A (ko) 레닌 억제제로서의 치환된 피페리딘
CN102548985A (zh) 取代羰基化合物
SK286687B6 (sk) Sulfónamidy, spôsob ich výroby, medziprodukty, liečivo a farmaceutická kompozícia s ich obsahom
SK13912003A3 (sk) 4-(Fenyl(piperidin-4-yl)amino)benzamidové deriváty a ich požitie na liečbu bolesti, anxiety alebo gastrointestinálnych porúch
ES2285179T3 (es) Derivados de fenil-piperidin-4-ilidene-metil-benzamida para el tratamiento de dolor o trastornos gastrointestinales.
JPWO2005030722A1 (ja) N−置換−n−(4−ピペリジニル)アミド誘導体